Exhibit
      31.1


Provectus
      Pharmaceuticals, Inc.


Certification
      Pursuant to Rule 13a-14(a)


Section
      302 Certification








I,
      H.
      Craig Dees, Ph.D., the Chief Executive Officer of Provectus Pharmaceuticals,
      Inc., certify that:





1.  
      I have reviewed this annual report on Form 10-KSB of Provectus Pharmaceuticals,
      Inc.;





2. 
      Based on my knowledge, this report does not contain any untrue statement of
      a
      material fact or omit to state a material fact necessary to make the statements
      made, in light of the circumstances under which such statements were made,
      not
      misleading with respect to the period covered by this report;





3. 
      Based on my knowledge, the financial statements, and other financial information
      included in this report, fairly present in all material respects the financial
      condition, results of operations and cash flows of  the small business
      issuer as of, and for, the periods presented in this report;





4. 
      The small business issuer's other certifying officer(s) and I are responsible
      for establishing and maintaining disclosure controls and procedures (as defined
      in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business
      issuer and have:





a)
      Designed such disclosure controls and procedures, or caused such disclosure
      controls and procedures to be designed under our supervision, to ensure that
      material information relating to the small business issuer, including its
      consolidated subsidiaries, is made known to us by others within those entities,
      particularly during the period in which this report is being
      prepared;




b)
      Evaluated the effectiveness of the small business issuer's disclosure controls
      and procedures and presented in this report our conclusions about the
      effectiveness of the  disclosure controls and procedures, as of the end of
      the period covered by this report based on such evaluation;




c)
      Disclosed in this report any change in the small business issuer's internal
      control over financial reporting that occurred during the small business
      issuer's most recent fiscal quarter that has materially affected, or is
      reasonably likely to materially affect, the small business issuer's internal
      control over financial reporting; and





5. 
      The small business issuer's other certifying officers and I have disclosed,
      based on our most recent evaluation of internal control over financial
      reporting, to the small business issuer's auditors and the audit committee
      of
      the small business issuer's board of directors (or persons performing the
      equivalent functions):





a) 
      All significant deficiencies and material weaknesses in the design or operation
      of internal control over financial reporting which are reasonably likely
      to adversely affect the small business issuer's ability to record, process,
      summarize and report financial information; and





b)  Any
      fraud, whether or not material, that involves management or other employees
      who
      have a significant role in the small business issuer's internal control
      over  financial reporting.





**Provectus
                Pharmaceuticals, Inc.**Date: March
                29, 2006
              By:
              /s/ H.
                Craig DeesH.
                Craig DeesTitle: 
                Chief Executive Officer